AbbVieABBVEarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Revenue
$15.1B
Gross Profit
$10.7B
Operating Profit
$-1.5B
Net Profit
$-22.0M
Gross Margin
70.9%
Operating Margin
-9.9%
Net Margin
-0.1%
YoY Growth
5.6%
EPS
$-0.03
AbbVie Q4 FY2024 Financial Summary
AbbVie reported revenue of $15.1B (up 5.6% YoY) for Q4 FY2024, with a net profit of $-22.0M (down 102.7% YoY) (-0.1% margin). Cost of goods sold was $4.4B, operating expenses totaled $12.2B.
Key Financial Metrics
| Total Revenue | $15.1B |
|---|---|
| Net Profit | $-22.0M |
| Gross Margin | 70.9% |
| Operating Margin | -9.9% |
| Report Period | Q4 FY2024 |
AbbVie Annual Revenue by Year
AbbVie annual revenue history includes year-by-year totals (for example, 2025 revenue was $61.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $61.2B |
| 2024 | $56.3B |
| 2023 | $54.3B |
| 2022 | $58.1B |
AbbVie Quarterly Revenue & Net Profit History
AbbVie results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $15.0B | +9.9% | $697.0M | 4.6% |
| Q4 FY2025 | $16.6B | +10.0% | $1.8B | 10.9% |
| Q3 FY2025 | $15.8B | +9.1% | $186.0M | 1.2% |
| Q2 FY2025 | $15.4B | +6.6% | $938.0M | 6.1% |
| Q1 FY2025 | $13.3B | +8.4% | $1.3B | 9.6% |
| Q4 FY2024 | $15.1B | +5.6% | $-22.0M | -0.1% |
| Q3 FY2024 | $14.5B | +3.8% | $1.6B | 10.8% |
| Q2 FY2024 | $14.5B | +4.3% | $1.4B | 9.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.46B | $14.46B | $15.10B | $13.34B | $15.42B | $15.78B | $16.62B | $15.00B |
| YoY Growth | 4.3% | 3.8% | 5.6% | 8.4% | 6.6% | 9.1% | 10.0% | 9.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $141.94B | $143.42B | $135.16B | $136.16B | $137.18B | $133.90B | $133.96B | N/A |
| Liabilities | $135.16B | $137.39B | $131.84B | $134.75B | $137.37B | $136.54B | $137.23B | N/A |
| Equity | $6.78B | $6.03B | $3.33B | $1.42B | $-183.0M | $-2.64B | $-3.27B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $2.27B | $5.45B | $7.05B | $1.64B | $5.15B | $7.02B | $5.22B |